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Introduction: The number of malpractice claims against physicians and health institutes is 
increasing continuously in Israel as in the rest of the Western world, and has become a serious 
financial burden.
Aim: In this study we analyzed the reports of gastroenterologists on endoscopic retrograde 
cholangiopancreatography (ERCP) and endoscopic ultrasound (EUS) adverse events to the risk 
management authority between January 1, 2000 and December 31, 2006.
Methods: All the reported adverse events associated with ERCP and EUS of health institutes 
and covered by Madanes Insurance Agency were summarized and analyzed. Clinical and 
epidemiological details about the patients, procedures, and adverse events were coded into an 
Excel worksheet, discussed, and evaluated.
Results: Forty-two cases of ERCP and EUS adverse events were reported. There were nine 
cases of men (21.4%) and the average age was 69.3 ± 14.3 years. During this period, 10,647 
procedures were performed by the institutes concerned and the number of adverse events was 
20.2 to 67.8 per year for 10,000 procedures. Perforation occurred in one out of 367 procedures, 
bleeding in one out of 5323 procedures, teeth trauma in one out of 5323 procedures, and respira-
tory complications in one out of 10,647 procedures.
Conclusion: This is the first study in Israel about physicians’ reports of ERCP and EUS adverse 
events. Physicians reported only about severe adverse events with high rate of mortality and 
morbidity.
Keywords: ERCP, EUS, defensive medicine, perforation, bleeding, sedation, risk   management, 
patient safety
Introduction
More than 60% of the Israeli population has a mandatory health insurance by Clalit 
Health Services (CHS). The physicians of CHS, in the community as well as in hos-
pitals, have malpractice insurance at the same company. The number of malpractice 
claims against physicians and health institutions is increasing continuously in Israel 
as in the rest of the Western world, and has become a serious financial burden. Health 
economy has become critically unstable, and strategies for decreasing claims and 
reducing losses have become an integral part of every health plan in Israel. It was 
recently reported that 93% and 98% of American and Japanese physicians, respec-
tively, practice defensive medicine, such as assurance behavior, as well as avoidance 
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Health organizations in Israel demand an immediate report 
of any error or complication in patients’ management. The 
report provides the insurer with an opportunity to prepare the 
defense for a potential claim, and to discuss the case when a 
personal or system failure is suspected. Sometimes   physicians 
are reluctant to report errors, facing a self-image or ego 
conflict, as well as peer and managerial criticism.   Intensive 
persuasive efforts of health organizations claiming that early 
reports are for the physician’s own benefit,   gradually overcome 
this problem and regular reporting increasingly approaches 
the rate of real life events. Still, significant under-reporting 
of medical complications is evident.
In this study, we analyzed the reports of CHS gastroenter-
ologists on endoscopic retrograde cholangiopancreatography 
(ERCP) and endoscopic ultrasound (EUS) adverse events to 
the Risk Management Authority, between January 1, 2000 
and December 31, 2006. We aimed to characterize reports of 
errors or complications in patients’ management by gastro-
enterologists performing ERCP and EUS for evaluation of 
bile duct and pancreatic diseases. Our paper is by all means 
not a review of procedure complications.
Methods
All the reports of physicians associated with ERCP and 
EUS adverse events or complications from health institutes 
covered by Madanes Insurance Company between January 1, 
2000 and December 31, 2006 were summarized by the authors 
during several meetings. Clinical and epidemiological details 
about the patients, procedure, and adverse events were coded 
into an Excel worksheet, discussed, and evaluated by all four 
researchers. Date, time of the day and place of the procedure, 
background diseases and operations, medications, indication, 
additional procedure such as sphincterotomy, dilatation, and 
biopsy, completeness of informed consent, treatment with 
anticoagulant or anti platelets adhesion agent, adverse events 
and the time of diagnosis, and treatment of complication and 
outcome were all thoroughly discussed and computed. The 
number of procedures performed for the members of CHS 
in Israel between 2000 and 2006 was extracted from the 
CHS database for each year of the study. The incidence of 
ERCP and EUS adverse events was separately calculated for 
  members of CHS according to the database for this period.
A quantum (Q) value, a parameter for a potential claim and 
its value in Israeli shekels, was calculated for each case, and 
assigned zero (no potential claim) or .zero (potential claim). 
Parameters that have impact on the Q value are:   severity of 
complication, pain, suffering, decrease in the   ability to work 
and salary (in relationship to income and family status), need 
of help for daily activity, potential changes in housing or 
relocation, life expectancy, expenses in the particular case, 
and experience with similar cases in the past.
Statistical analysis was performed using SPSS (v 13; 
IBM, Petach Tikva, Israel). The results are expressed as 
mean ± standard deviation; P , 0.05 were considered 
  significant. Kruskal–Wallis, Mann–Whitney, Chi-square, 
and ANOVA tests were used as needed.
Results
Forty-two cases of ERCP and EUS adverse events were 
reported to Madanes Insurance Company between January 1,   
2000 and December 31, 2006; 38 cases (90.5%) of them 
belong to CHS. Clinical and demographic data of the cases are 
presented in Table 1. There were nine cases of men (21.4%) 
and the average age was 69.3 ± 14.3 years, range 7–87 years, 
median 71 years. Thirty-four patients (80.9%) were 65 years 
or older. Thirty-five events (83.3%) were reported voluntarily 
by the staff (primary report), and seven (16.7%) were reported 
after a claim was submitted (secondary report). Most of the 
procedures were for therapeutic reasons and performed on 
an elective basis. More than 50% of the patients had two 
or more chronic background diseases, had undergone two 
Table 1 Demographic and clinical data of the reported cases, 
N = 42 (100%)
Parameter N %
Sex
Men 9 21.4
Women 33 78.6
Age
Average ± standard deviation (y) 69.3 ± 14.3
Median (y) 71
range (y) 7–87
.65 years 34 80.9
Referral center
Hospital 41 97.6
community unit 1 2.4
State of urgency
elective 23 54.8
Urgent 19 45.2
Procedure characteristics
Diagnostic ercP 8 19.0
Therapeutic ercP 27 64.3
eUS 7 16.7
Record of two or more chronic diseases 21 50.0
Record of two or more operations 31 73.8
Record of two or more medications 30 71.4
Anticoagulant or antiplatelet therapy
None 22 52.4
Aspirin 14 33.3
coumadin 1 2.4
Unknown 5 11.9Drug, Healthcare and Patient Safety 2011:3 submit your manuscript | www.dovepress.com
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or more operations, and were regularly treated with two or 
more medications, including aspirin (33.3%) and coumadin 
(2.4%).
Distribution of the ERCP and EUS adverse events during 
a 7-year period for CHS members is demonstrated in Table 2. 
During this period, 10,647 ERCP and EUS were performed 
by the institutes concerned. The number of adverse events 
was between 20.2 and 67.8 per year for 10,000 procedures. 
The difference between the years was not statistically 
  significant. Perforation occurred in one out of 367 procedures, 
bleeding in one out of 5323 procedures, teeth trauma in one 
out of 5323 procedures, and respiratory complications in one 
out of 10,647 procedures.
Distribution of the adverse events along the week working 
days was between 11.9% minimum and 42.9% maximum 
on Monday and Thursday, respectively. Thirty-two events 
(76.2%) occurred in the morning and two (4.8%) in the 
afternoon. Informed consent was properly filled and signed 
in 30 cases (71.4%), and partially filled in three additional 
cases (7.1%). The informed consent form could not be found 
in the patients files in nine cases (21.4%).
Description of adverse events and clinical outcome is 
  demonstrated in Table 3. There were 29 perforations, 69% of 
the adverse events. Most of the cases were detected and reported 
immediately or within 24 hours. The 29 patients were operated 
upon (69%), but all required hospitalization. The majority of the 
involved patients suffered critical outcomes: 15 mortality cases 
(35.7%) and 18 patients (42.9%) had residual damage.
The status of legal claims is presented in Table 4. Only 
a minority of the cases was debated in court; seven ended 
with compromise agreements and two are engaged in ongo-
ing negotiations.
The Q value was zero in 13 cases (31%), and 100,000 
or higher in seven cases (16.6%); mean = 50,022 ± 93,478, 
median = 20,000, and range 0–54,023 new Israeli Shekel 
(NIS).
Table 2 Distribution of ercP and eUS adverse events during 
7-year period for cHS members
Year Number of  
adverse  
events
Number of  
procedures  
performed
Number of adverse   
events per 10,000  
procedures
2000 5 883 56.6
2001 4 964 41.5
2002 13 1917 67.8
2003 4 1972 20.2
2004 5 1986 25.2
2005 4 1583 25.3
2006 7 1342 52.2
Total 42 10,647 39.5
Table 3 Adverse events in ercP and eUS, N = 42 (100%)
Parameter N %
Complication
Perforation 29 69.0
Bleeding 2 4.8
cardiovascular and respiratory event 1 4.8
Teeth trauma 2 2.4
Other 8 19.0
Time detected
immediately 23 54.8
Within 24 hours 13 31.0
More than 24 hours 3 7.1
Unknown 3 7.1
Treatment
Operation 29 69.0
Hospitalization and conservative treatment 7 16.7
Ambulatory treatment 4 9.6
Unknown 2 4.7
Outcome
residual damage 18 42.9
complete healing 6 14.3
Death 15 35.7
Unknown 3 7.1
Table 4 claims and legal status for July 16, 2010
Parameter N %
court litigation 2 4.8
compromise agreement 7 16.6
Limitation 11 26.2
Other 22 52.4
Discussion
Reporting adverse events and complications is part of daily 
routine work in Israeli medicine encouraged by the health 
organizations and the insurance companies, but not sup-
ported by objective measures.3 With sensational mass media 
reporting on medical malpractice, physicians have begun 
to focus on risk management activities leading them to 
practice defensive medicine. This strategy enables prepara-
tion for potential claims, collecting specific data, assigning 
dedicated sums of money by the insurance company, and 
also collecting data for the purpose of quality assurance 
measurements.
Described adverse events and complications of ERCP 
and EUS included perforation, bleeding, sedation associ-
ated cardiovascular and respiratory problems, and missing 
or misinterpreting lesions.4
The manner in which the incident is handled has impor-
tant consequences for the affected patients’ decision to 
take legal action.5,6 Complete disclosure of adverse event 
or near-miss situations to the patients and family members Drug, Healthcare and Patient Safety 2011:3 submit your manuscript | www.dovepress.com
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may prevent lawsuits, but this strategy is not always practiced 
because of shame, embarrassment, fear of losing trust, and 
lack of training.7–10
The most important complication of ERCP and EUS is 
perforation. The incidence of perforation is estimated to be 
0.5%.4 In our reported series, it ranges from 0.075% following 
diagnostic procedures to 0.25% following interventions.
In the present paper, we described 42 cases of adverse 
events during ERCP and EUS reported to the Madanes Insur-
ance Company in a 7-year period. Not surprisingly, most 
of the cases were of elderly patients with a background of 
chronic diseases. The rate of perforation was well within the 
accepted range described in the literature, and most of them 
happened in therapeutic procedures. The rarity of respira-
tory and cardiovascular complication, most probably due to 
sedation, is outstanding. Only one case was reported, thus a 
ratio of one in 10,647 procedures could be calculated. The 
clinical outcome was not so favorable. There were 15 cases 
of mortality and 29 patients underwent operation. Eighteen 
patients were left with residual damage.
Most of the complications were diagnosed early, 54.8% 
immediately after the procedure and an additional 31% within 
24 hours. In 13 cases the Q value was zero and no further 
legal evaluation should be performed, while in seven cases 
the Q value was 100,000 and higher, and these cases were 
evaluated thoroughly for potential litigations and financial 
compensation.
It is not possible to estimate the true rate of adverse events 
according to these voluntary reports. We believe that there 
are far more cases than reported. Milch et al analyzed 92,547 
reports from 26 acute care hospitals and found a wide report-
ing rate difference across hospitals, nine to 95 reports per 
1,000 inpatient-days (median = 35).9 Thus, reporting should 
be improved. Vincent et al described four main reasons for 
litigation: concern with standard of care, the need for explana-
tion, compensation, and accountability.10 Reporting adverse 
events is an essential component in the training of staff and 
organizations that should have to account for their actions. 
In a survey of teaching hospitals, Kaldjian et al demonstrated 
that most faculty and resident physicians are inclined to report 
harm-causing hypothetical errors, but only a minority has 
actually reported an error.8
Being an insurance company, Madanes receives reports 
that are basically major events with evident damage to the 
patient, ie, the probability of a claim is fairly high. When ana-
lyzing the events in our cohort we observed the phenomenon 
that almost 80% of the reported events resulted in death of 
the patient or residual damage.
According to Heinrich’s Iceberg model,8 for each severe 
accident there are 29 accidents with minor damages and 
300 accidents with marginal damages or without damages 
at all. It may be calculated that the real numbers of adverse 
events in the analyzed 7-year period should be as follows: 33 
reported adverse events involving fatality or residual damage, 
957 adverse events with minor damages, and 9900 adverse 
events with marginal damage or no damage at all – “near 
misses”. We can assume that in this article we analyzed the tip 
of the iceberg assuming that the insured institutions reported 
the severe occurrences to the insurer and avoided reporting 
the less severe occurrences. Kern investigated 99 malpractice 
cases that came to trial in the United States federal and state 
civil court system, involving 103 allegations of negligence 
over a 21-year period.12 There were 44 cases of misdiagno-
sis, 25 cases of iatrogenic injury, and 16 cases of medical 
complication. In eight cases (8%), lack of informed consent 
was the reason for litigation. This series is different from our 
cohort, where misdiagnosis was not part of it.
Our study is limited by being retrospective and by a 
lack of essential data from the patients’ files and source 
  documents. In addition, the follow-up is too short to evaluate 
the legal outcome of this cohort. We do not have information 
about the number of patients that still can sue or complain. 
This paper is about “physicians’ reports”, and should be 
accepted as such. One should learn about reporting habits 
of gastroenterologists performing EUS and ERCP from our 
data, and not to assess the safety of the procedures.
Conclusion
This is the first study in Israel about physicians’ reports of 
ERCP and EUS adverse events. Physicians only reported 
severe adverse events with a high rate of mortality and 
morbidity.
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